Latest News

Pharmacists can educate patients about FluMist for at-home administration and opioid labeling changes.

This review examines the mechanisms of therapy, summarizes the existing literature, and highlights the evolving treatment options for unresectable hepatocellular carcinoma.

Findings from a meta-analysis reveal biosimilars for inflammatory bowel disease (IBD) offer similar efficacy and safety and maintained remission rates as their reference products.

Biosimilars are set to revolutionize oncology by enhancing access and affordability while maintaining safety and efficacy.

Discover how GLP-1 receptor agonists may benefit breast cancer patients by promoting weight loss and improving long-term health outcomes.

ctDNA analysis revolutionizes cancer treatment by predicting responses, detecting resistance, and monitoring minimal residual disease in patients.

FDA approves depemokimab-ulaa as a long-acting treatment for severe asthma, enhancing patient care with fewer injections and improved outcomes.

Previously approved for patients 12 years and older, berotralstat now gives younger patients a treatment option to manage sudden hereditary angioedema attacks.

FDA approves zoliflodacin, a groundbreaking oral treatment for gonorrhea, offering hope against antibiotic resistance and improving patient access.

FDA grants a national priority voucher to teclistamab and daratumumab for relapsed/refractory multiple myeloma, enhancing treatment approval speed.

Second-line and later treatment options for synovial sarcoma are limited. Afamitresgene autoleucel is the first FDA-approved T-cell receptor therapy, demonstrating long-lasting responses and tolerable adverse effects in pretreated patients.

Nonadherence has negative impacts on patients, health systems, and society.

The approval is supported by findings from the phase 3 DESTINY-Breast09 trial.

Thyroid Diseases Can Have Widespread Physiological Effects

The FDA-approved flibanserin represents the first and only once-daily oral pill for postmenopausal women with hypoactive sexual desire disorder.

Retatrutide shows promising results in reducing weight and knee pain for individuals with obesity and osteoarthritis, enhancing physical function significantly.

The FDA has approved etripamil as the first and only self-administered nasal spray for adults with paroxysmal supraventricular tachycardia (PSVT), offering a rapid, effective treatment that can be used outside of health care settings.

Pharmacists play a vital role in modern clinical trials, enhancing patient safety and trial efficiency through drug management and protocol development.

Lerodalcibep, a new PCSK9 inhibitor, offers a convenient monthly injection to effectively lower LDL cholesterol in patients with hypercholesterolemia.

Pharmacy leaders at ASHP Midyear 2025 highlight urgent concerns about future uncertainties and preparedness for crises impacting health systems and patient care.